TherapeuticsMD, Inc.

Regulatory Filings • May 16, 2013

8-K 1 txmd-8k_051613.htm CURRENT REPORT txmd-8k_051613.htm Licensed to: Quality Edgar Solutions Document Created using EDGARizerAgent 5.4.4.0 Copyright 1995 - 2013 Thomson Reuters. All rights reserved.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 16, 2013

THERAPEUTICSMD, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-16731	87-0233535
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

951 Broken Sound Parkway NW, Suite 320, Boca Raton, FL 33487

(Address of principal executive offices and Zip Code)

(561) 961-1911

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2 below):

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 16, 2013, our Board of Directors elected Jules A. Musing to serve as an additional member of our Board of Directors. Mr. Musing will serve until our next annual meeting of shareholders or until his successor is duly elected and qualified or until his earlier resignation or removal. There is no arrangement or understanding between us and Mr. Musing or any other person pursuant to which he was elected as a director, and there are no related party transactions with respect to Mr. Musing reportable under Item 404(a) of Regulation S-K. It has not yet been determined on which Board committees Mr. Musing will serve.

In the course of Mr. Musing's 36-year career in the pharmaceutical and biotechnology industry, specifically at Johnson & Johnson, he has been responsible for the worldwide licensing and acquisition of pharmaceutical and biotechnology products and technologies and the establishment of strategic alliances. This included the establishment of new scientific, technology and product collaborations in various therapeutic areas, the negotiation of licensing and alliance agreement with biotechnology and pharmaceutical companies worldwide, and the partnering, spin-out and out-licensing of company pharmaceutical and biotechnology assets. Mr. Musing received his Master’s Degree in Biological Sciences from the University of Brussels (Belgium) and his Graduate Degree in Economics and Financial Sciences from the University of Antwerp (Belgium).

We issued a press release announcing the election of Mr. Musing on May 16, 2013, a copy of which is attached as Exhibit 99.1 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number Description

99.1 Press Release from TherapeuticsMD, Inc., dated May 16, 2013, entitled “TherapeuticsMD Elects Jules A. Musing to Board of Directors. ”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THERAPEUTICSMD, INC. — By:	/s/ Robert G. Finizio
Name:	Robert G. Finizio
Title:	Chief Executive Officer

EXHIBIT INDEX

Exhibit Number Description

99.1 Press Release from TherapeuticsMD, Inc., dated May 16, 2013, entitled “TherapeuticsMD Elects Jules A. Musing to Board of Directors. ”